MA45277A - Promédicaments de pth - Google Patents

Promédicaments de pth

Info

Publication number
MA45277A
MA45277A MA045277A MA45277A MA45277A MA 45277 A MA45277 A MA 45277A MA 045277 A MA045277 A MA 045277A MA 45277 A MA45277 A MA 45277A MA 45277 A MA45277 A MA 45277A
Authority
MA
Morocco
Prior art keywords
pth
medicines
Prior art date
Application number
MA045277A
Other languages
English (en)
Inventor
Felix Cleemann
Mathias Krusch
Guillaume Maitro
Kennett Sprogøe
Thomas Wegge
Joachim Zettler
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MA45277A publication Critical patent/MA45277A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Marine Sciences & Fisheries (AREA)
MA045277A 2016-03-01 2017-02-28 Promédicaments de pth MA45277A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16158048 2016-03-01
EP16179294 2016-07-13
EP16191484 2016-09-29
EP17155839 2017-02-13

Publications (1)

Publication Number Publication Date
MA45277A true MA45277A (fr) 2019-01-09

Family

ID=58185540

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045809A MA45809A (fr) 2016-03-01 2017-02-28 Promédicaments de pth
MA045277A MA45277A (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA045809A MA45809A (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Country Status (17)

Country Link
US (6) US20200276276A1 (fr)
EP (1) EP3423103B1 (fr)
JP (2) JP7059195B2 (fr)
KR (3) KR20230015517A (fr)
CN (2) CN109069659B (fr)
AU (4) AU2017227962C1 (fr)
BR (1) BR112018017091A2 (fr)
CA (1) CA3015585A1 (fr)
IL (2) IL260756B2 (fr)
MA (2) MA45809A (fr)
MX (2) MX2018009938A (fr)
MY (1) MY196308A (fr)
NZ (1) NZ745318A (fr)
RU (1) RU2747316C2 (fr)
SG (1) SG11201806092TA (fr)
WO (1) WO2017148883A1 (fr)
ZA (1) ZA201805705B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
RU2747316C2 (ru) * 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
EP3518982A1 (fr) * 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases A/S Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
JP7085535B2 (ja) 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス ピーク対トラフ比が小さいｐｔｈ化合物
KR20230066147A (ko) 2016-09-29 2023-05-12 아센디스 파마 그로우쓰 디스오더스 에이/에스 조절 방출 cnp 아고니스트를 사용한 병용 요법
EP4275677A3 (fr) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Schéma posologique pour composé pth à libération controlée
US11975050B2 (en) 2018-03-16 2024-05-07 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
CA3093722A1 (fr) * 2018-03-28 2019-10-03 Ascendis Pharma Oncology Division A/S Conjugues d'il-2
US20210196801A1 (en) * 2018-05-18 2021-07-01 Ascendis Pharma Bone Diseases A/S Starting Dose of PTH Conjugates
CN113840625A (zh) 2019-01-29 2021-12-24 夏尔-Nps医药品有限公司 甲状旁腺激素变体
SG11202107722VA (en) * 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
CA3178074A1 (fr) 2020-06-03 2021-12-09 Nina Gunnarsson Sequences d'il-2 et leurs utilisations
WO2021263040A1 (fr) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Formulations de pepticorps stables
EP4192508A1 (fr) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugués comprenant des lieurs réversibles et leurs utilisations
WO2024094673A1 (fr) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Régime de traitement à base de pth comprenant deux composés pth

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1477496A4 (fr) 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd Pth a liaison peg ou derive de pth a liaison peg
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
ES2512499T3 (es) 2003-04-08 2014-10-24 Yeda Research And Development Co., Ltd. Fármacos pegilados reversibles
JP4133570B2 (ja) * 2003-05-15 2008-08-13 アルパイン株式会社 ナビゲーション装置
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
CN1657540A (zh) * 2004-02-18 2005-08-24 中国人民解放军军事医学科学院基础医学研究所 人甲状旁腺素（1－34）的聚乙二醇化衍生物，含有它们的药物组合物及用途
CA2824093C (fr) 2004-03-23 2016-10-25 Complex Biosystems Gmbh Liant de promedicament
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) * 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
EP1799759A1 (fr) 2004-08-30 2007-06-27 Lunamed Inc. Formulations a liberation controlee d'acide 4-phenylbutyrique utilisees dans des traitements
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
WO2007106597A2 (fr) 2006-03-15 2007-09-20 Alza Corporation Appareil et procede d'administration transdermique d'agents hormonaux parathyroidiens destines a traiter ou prevenir l'osteopenie
NO325064B1 (no) * 2006-07-06 2008-01-28 Tandberg Telecom As Kommunikasjonsklient
WO2008034122A2 (fr) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Segments de liaison biodégradables à base d'ester encombré pour distribution d'oligonuclotides
PL2084183T3 (pl) * 2006-10-13 2010-10-29 Lilly Co Eli Pegylowane pth jako modulatory receptora pth i ich zastosowania
US8101729B2 (en) 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
DK3091075T3 (en) 2007-04-09 2018-07-16 Univ Arkansas FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYRO OIDA HORMON
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
JP2010533202A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 多置換芳香族部分を含むポリマー性薬剤送達システム
EP2052736A1 (fr) 2007-10-26 2009-04-29 Nycomed Danmark ApS Formulations d'hormones parathyroïdiennes et leurs utilisations
US8906847B2 (en) * 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
LT3050576T (lt) 2008-04-29 2021-07-12 Ascendis Pharma Endocrinology Division A/S Pegiliuoti rekombinantinio žmogaus augimo hormono junginiai
EP2288261A4 (fr) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d oligonucléotides
WO2009156481A1 (fr) 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
WO2010022171A1 (fr) 2008-08-19 2010-02-25 Ferring International Center S.A. Agonistes du récepteur de pth peptidique
CA2748314C (fr) 2009-02-03 2018-10-02 Amunix Operating Inc. Polypeptides recombinants etendus et compositions les comprenant
UA108475C2 (uk) 2009-07-31 2015-05-12 Санофі-Авентіс Дойчланд Гмбх Композиція інсуліну тривалої дії
WO2011012723A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Compositions injectables à libération prolongée contenant un promédicament du pramipexole
EP2459225A1 (fr) 2009-07-31 2012-06-06 Ascendis Pharma A/S Promédicaments de pramipexole liés à un support
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
SI2459220T1 (sl) 2009-07-31 2020-12-31 Ascendis Pharma A/S Biorazgradljivi v vodi netopni hidrogeli na osnovi polietilenglikola
EP2459227B1 (fr) 2009-07-31 2021-03-17 Ascendis Pharma A/S Promédicaments contenant une amine aromatique liée à un support par liaison amide
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
AU2010332958B2 (en) * 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2519228A4 (fr) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc Conjugués polymères de composés contenant un groupement amine aromatique comprenant un lieur d'urée libérable
EP2525829A1 (fr) 2010-01-22 2012-11-28 Ascendis Pharma A/S Lieurs de promédicaments à base de dipeptides pour des médicaments à teneur en amine aromatique
EP2525830B1 (fr) 2010-01-22 2016-05-11 Ascendis Pharma A/S Liens de promédicaments à base de dipeptides pour médicament contenant des amines aliphatiques
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20110229580A1 (en) 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
WO2011123813A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
CN103025165B (zh) 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
PL2571510T3 (pl) 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
WO2012002047A1 (fr) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 Procédé de détermination d'attributs, dispositif de détermination d'attributs, programme, support d'enregistrement et système de détermination d'attributs
US20120040320A1 (en) 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
MX2014001496A (es) 2011-08-12 2014-04-30 Ascendis Pharma As Composicion de liberacion sostenida de prostaciclina.
EP2741744A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments reliés à des supports comprenant des liaisons ester carboxylique réversibles
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
CA2843503C (fr) 2011-08-12 2020-12-22 Ulrich Hersel Promedicaments lies a des excipients polymeriques hyperbranches
EP2741782B1 (fr) 2011-08-12 2020-05-06 Ascendis Pharma A/S Prodrogues liés à un support protéinique
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
SG11201400815TA (en) 2011-10-12 2014-09-26 Ascendis Pharma Ophthalmology Division As Prevention and treatment of ocular conditions
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
US20150087688A1 (en) 2012-04-25 2015-03-26 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US9718868B2 (en) * 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
WO2014056926A1 (fr) 2012-10-11 2014-04-17 Ascendis Pharma A/S Promédicaments sous forme d'hydrogel
RU2682676C2 (ru) 2012-10-11 2019-03-20 Асцендис Фарма Ас Диагностика, профилактика и лечение болезней суставов
NZ706853A (en) 2012-10-11 2018-04-27 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
JP6290243B2 (ja) 2012-12-07 2018-03-07 アセンディス ファーマ エー／エス 担体連結プロスタノイドプロドラッグ
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
WO2015031709A1 (fr) 2013-08-30 2015-03-05 Perosphere, Inc. Formulations injectables à action rapide comprenant un peptide et un agent vasodilatateur
US10040850B2 (en) 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (fr) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptides inhibiteurs de l'interaction TEAD/YAP-TAZ
CA2955569C (fr) 2014-08-06 2023-02-14 Ascendis Pharma A/S Promedicaments comprenant un lieur de type aminoalkylglycine
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
SG11201705521YA (en) 2015-01-09 2017-08-30 Ascendis Pharma Growth Disorders As Cnp prodrugs
RU2747316C2 (ru) 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
EP3518982A1 (fr) 2016-09-29 2019-08-07 Ascendis Pharma Bone Diseases A/S Schéma posologique incrémentiel dans des composés de pth à libération contrôlée
JP7085535B2 (ja) * 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス ピーク対トラフ比が小さいｐｔｈ化合物
EP4275677A3 (fr) * 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Schéma posologique pour composé pth à libération controlée
KR20230066147A (ko) * 2016-09-29 2023-05-12 아센디스 파마 그로우쓰 디스오더스 에이/에스 조절 방출 cnp 아고니스트를 사용한 병용 요법
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
US20210196801A1 (en) * 2018-05-18 2021-07-01 Ascendis Pharma Bone Diseases A/S Starting Dose of PTH Conjugates
SG11202107722VA (en) * 2019-02-11 2021-08-30 Ascendis Pharma Bone Diseases As Liquid pharmaceutical formulations of pth conjugates
MX2022007371A (es) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.

Also Published As

Publication number Publication date
KR20230015517A (ko) 2023-01-31
AU2017227962C1 (en) 2021-05-13
US20200276276A1 (en) 2020-09-03
KR20180118197A (ko) 2018-10-30
AU2020286303B2 (en) 2022-07-21
MY196308A (en) 2023-03-24
EP3423103B1 (fr) 2024-09-11
AU2017227962A1 (en) 2018-08-09
MX2018009938A (es) 2019-03-14
KR102331820B1 (ko) 2021-11-29
US20220008516A1 (en) 2022-01-13
CN109069659B (zh) 2022-04-19
MX2022015755A (es) 2023-01-19
RU2018134135A (ru) 2020-04-01
CA3015585A1 (fr) 2017-09-08
JP7059195B2 (ja) 2022-04-25
AU2022256158A1 (en) 2022-12-08
AU2017227962B2 (en) 2020-11-12
RU2018134135A3 (fr) 2020-04-01
US20200376089A1 (en) 2020-12-03
US20230121525A1 (en) 2023-04-20
IL260756A (fr) 2018-09-20
AU2022256158A9 (en) 2023-09-28
EP3423103A1 (fr) 2019-01-09
RU2747316C2 (ru) 2021-05-04
MA45809A (fr) 2019-01-09
AU2020286303A1 (en) 2021-02-04
JP2022068210A (ja) 2022-05-09
WO2017148883A1 (fr) 2017-09-08
SG11201806092TA (en) 2018-08-30
AU2022256158B2 (en) 2023-09-28
ZA201805705B (en) 2019-06-26
US11793861B2 (en) 2023-10-24
US20240123038A1 (en) 2024-04-18
IL260756B2 (en) 2023-09-01
NZ745318A (en) 2023-01-27
KR20210147085A (ko) 2021-12-06
US20200360487A1 (en) 2020-11-19
AU2020286303C1 (en) 2023-03-02
KR102524255B1 (ko) 2023-04-20
AU2023285850A1 (en) 2024-01-18
JP2019513127A (ja) 2019-05-23
IL260756B1 (en) 2023-05-01
BR112018017091A2 (pt) 2019-01-02
CN109069659A (zh) 2018-12-21
IL301616A (en) 2023-05-01
CN115025239A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
MA45277A (fr) Promédicaments de pth
CL2015003730S1 (es) Automóvil
CL2015003114S1 (es) Automovil
UA32547S (uk) Автомобіль
CL2015002393S1 (es) Automóvil
CL2015001896S1 (es) Vehiculo
CL2015003626S1 (es) Automóvil
CL2016000247S1 (es) Automovil
DK3341479T3 (da) LNA-G-Proces
CL2015001956S1 (es) Automovil
CL2015003383S1 (es) Automóvil
MA43957A (fr) Biomarqueurs de copanlisib
CL2016000675S1 (es) Automóvil
CL2016000116S1 (es) Automóvil
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
CL2015003155S1 (es) Automóvil
DK3597189T3 (da) Krystallinske forbindelser
CL2015002005S1 (es) Automovil
CL2015001801S1 (es) Automovil
CL2015002006S1 (es) Automovil
CL2014002313S1 (es) Aparato de iluminacion
DE112017000734A5 (de) Glycolsensor
ES2789757T8 (es) Herramienta de conformado
BR112018004842A2 (pt) Veículo
ES1154210Y (es) Dispositivo de automasaje